A Fair Question, and One the Research Can Finally Answer

The body, as it turns out, is not always a reliable self-repair service. It loses paperwork, misfiles requests, and occasionally decides that a chronically irritated tendon deserves nothing more than scar tissue and a polite suggestion to try a different sport. PRP therapy in Clarksville, like most regenerative treatments, arrived with considerable fanfare and equally considerable skepticism. Neither response was entirely wrong. What's changed is that the research has matured enough to offer a clearer picture of when PRP earns its cost and when it doesn't.

This article addresses the most common questions patients bring to consultations, with answers grounded in the current clinical literature rather than the promotional language that tends to surround biologic treatments.

Q: What exactly is PRP, and why does it work for some people but not others?

Platelet-rich plasma is prepared by drawing a small blood sample, spinning it in a centrifuge to concentrate the platelet content well above normal circulating levels, and injecting the result directly into damaged tissue. Platelets contain growth factors, including PDGF, TGF-beta, and IGF-1, that signal the body to initiate tissue repair. The theory is reasonable: deliver more of the biological instruction set where the damage is, and the repair process that stalled gets restarted.

Why it works for some and not others comes down to three factors: diagnosis accuracy, preparation method, and tissue type. PRP is not a single, standardized product. Leukocyte content, platelet concentration, and activation method all vary between preparations and produce meaningfully different clinical outcomes. A 2022 systematic review covering 33 studies and over 2,400 lateral epicondylitis patients found success rates ranging from 36% to 100% depending on preparation type, which is a range wide enough to mean that preparation method is not a minor technical detail.

Additionally, PRP works most reliably in conditions with a degenerative rather than acute inflammatory pathology. Tendons that have failed to heal properly because the normal repair cycle collapsed, not tendons in the middle of active acute inflammation, are generally the better candidates.

Q: How does PRP compare to a cortisone shot, which seems simpler and cheaper?

Cortisone wins in the short term. Corticosteroid injections provide faster, more predictable relief in the first six to eight weeks, which is genuinely useful when pain is affecting daily function immediately. That advantage, however, tends to invert over time.

A 2025 meta-analysis of randomized controlled trials comparing PRP injections to corticosteroids for lateral epicondylitis, published in Clinical Shoulder and Elbow by researchers at the Rothman Orthopaedic Institute, found that while corticosteroids provided significantly better short-term pain relief, PRP produced better long-term functional improvement and sustained pain reduction beyond six months. Repeated corticosteroid use is also associated with tendon weakening over time, which is a structural concern that biologic alternatives do not carry.

For patients managing an acute flare before a specific event, cortisone is a rational choice. For those dealing with a chronic tendinopathy that has persisted for months or years, the evidence increasingly favors PRP as the more durable option.

Q: What conditions respond best to PRP?

The clearest evidence for PRP currently supports lateral epicondylitis (tennis elbow) and adhesive capsulitis of the shoulder. A 2025 review in JSES Reviews, Reports and Techniques concluded that PRP shows the strongest efficacy data in these two conditions specifically, noting that preparation methods, dosing, and injection frequency still lack standardization across other applications.

Beyond those two, PRP is used for:

  • Medial epicondylitis (golfer's elbow) with solid functional outcome data
  • Patellar tendinopathy, with moderate supporting evidence
  • Knee osteoarthritis, where multiple RCTs show pain and function improvement versus hyaluronic acid
  • Plantar fasciitis, as a secondary-line treatment after conservative measures

Achilles tendinopathy is an area where results are more mixed. A 2025 umbrella review covering systematic reviews through June 2025 found that PRP did not demonstrate statistically significant advantages over control treatments for chronic Achilles tendinopathy when outcomes were assessed beyond the short term. That finding does not disqualify PRP for every Achilles presentation, but it should temper expectations and inform case selection.

Q: What does a well-run PRP treatment program actually look like?

The injection is not the whole program. Patients who receive PRP as a standalone procedure without any structured rehabilitation tend to achieve less complete outcomes than those who combine it with targeted physical therapy. The biologic signal delivered by PRP creates a window of enhanced tissue receptivity that is most productive when the surrounding musculature and movement patterns are also being addressed.

A credible program includes: diagnostic imaging or clinical assessment to confirm the target tissue and rule out structural pathology that PRP cannot address; ultrasound guidance during injection to ensure accurate placement; and a physical therapy plan that begins within a few weeks of injection, timed to match the tissue's healing trajectory rather than arbitrary milestones.

Prior corticosteroid use at the injection site warrants attention. A 2025 retrospective study found that patients who had received corticosteroid injections before PRP showed poorer outcomes than those who had not, which suggests that the structural and biological environment of the tendon at the time of PRP delivery affects results.

The Honest Takeaway

PRP therapy in Clarksville has moved past the phase where it was either dismissed as expensive placebo or celebrated as universally transformative. For the right condition, in the right candidate, administered with appropriate preparation and supported by rehabilitation, it delivers outcomes that cortisone cannot sustain and surgery may not be necessary to justify. For the wrong condition or as a standalone procedure without clinical oversight, it remains an expensive lesson in misapplied biology. The body's repair mechanisms are not particularly impressed by enthusiasm. They respond to precision.